Guo Yi, Jiang Li
Department of Neurology, Children's Hospital, Chongqing University of Medical Science, Chongqing, China.
Neurol Res. 2010 Feb;32(1):106-12. doi: 10.1179/174313209X408954. Epub 2009 Jun 30.
Pharmacoresistance is a common problem hindering treatment of epilepsy. A possible cause for this resistance is the overexpression of efflux drug transporters, e.g. P-glycoprotein (P-gp), which may decrease extracellular antiepileptic drugs levels in brains of intractable epilepsy patients. Another transmembrane drug transporter is the organic anion transporting polypeptide 2 (Oatp2), which is colocalized with P-gp in many polarized tissues. However, a role for Oatp2 in the development of multidrug resistance has not been established. In the present work, we investigated the expression of drug transporters Oatp2 and P-gp in brain, liver and kidney of rats with chronic epilepsy induced by lithium-pilocarpine.
Chronic epilepsy was elicited after status epilepticus (SE) induced by lithium-pilocarpine in adult Wistar rats. Following SE, expression of Oatp2 and P-gp protein was detected by immunohistochemistry and Western blot analysis and messenger RNA (mRNA) using reverse transcription polymerase chain reaction (RT-PCR). Levels of the drug transporters were compared in brain, liver and kidney of chronic epileptic and control rats.
Both Oatp2 and P-gp were expressed in the brain, liver and kidney but predominantly in the brain. In the brain, Oatp2 and P-gp immunopositive cells were observed in brain capillary endothelium and choroid plexus epithelium. Compared with control rats, Oatp2 protein expression in brain was significantly decreased, while P-gp was obviously increased in chronic epileptic rats. P-gp mRNA was also significantly higher in brains of chronic epileptic rats, whereas the expression of Oatp2 did not change. Organic anion transporting polypeptide 2 and P-gp did not change at the mRNA or protein level with epilepsy in the liver or kidney.
Organic anion transporting polypeptide 2 and P-gp colocalized in tissues that are important in drug absorption, metabolism and excretion. Seizures seem to induce the cerebral changes of P-gp and Oatp2. However, the changes of expression of two transporters exhibit the opposite trend. Organic anion transporting polypeptide 2 might play a different role than P-gp in intractable epilepsy. Our data provide a basis for the assessment of the role of uptake transporters and efflux pumps in the development of intractable epilepsy.
药物抵抗是阻碍癫痫治疗的常见问题。这种抵抗的一个可能原因是外排药物转运体的过度表达,例如P-糖蛋白(P-gp),它可能会降低难治性癫痫患者大脑中细胞外抗癫痫药物的水平。另一种跨膜药物转运体是有机阴离子转运多肽2(Oatp2),它在许多极化组织中与P-gp共定位。然而,Oatp2在多药耐药性发展中的作用尚未明确。在本研究中,我们调查了锂-匹罗卡品诱导的慢性癫痫大鼠脑、肝和肾中药物转运体Oatp2和P-gp的表达。
在成年Wistar大鼠中,通过锂-匹罗卡品诱导癫痫持续状态(SE)后引发慢性癫痫。SE后,采用免疫组织化学和蛋白质印迹分析检测Oatp2和P-gp蛋白的表达,并使用逆转录聚合酶链反应(RT-PCR)检测信使核糖核酸(mRNA)。比较慢性癫痫大鼠和对照大鼠脑、肝和肾中药物转运体的水平。
Oatp2和P-gp在脑、肝和肾中均有表达,但主要在脑中表达。在脑中,在脑毛细血管内皮和脉络丛上皮中观察到Oatp2和P-gp免疫阳性细胞。与对照大鼠相比,慢性癫痫大鼠脑中Oatp2蛋白表达显著降低,而P-gp明显增加。慢性癫痫大鼠脑中P-gp mRNA也显著升高,而Oatp2的表达没有变化。在肝或肾中,有机阴离子转运多肽2和P-gp在mRNA或蛋白质水平上并未因癫痫而发生改变。
有机阴离子转运多肽2和P-gp在对药物吸收、代谢和排泄至关重要的组织中共定位。癫痫发作似乎会诱导P-gp和Oatp2的脑部变化。然而,两种转运体表达的变化呈现相反趋势。在难治性癫痫中,有机阴离子转运多肽2可能发挥与P-gp不同的作用。我们的数据为评估摄取转运体和外排泵在难治性癫痫发展中的作用提供了依据。